Eli Lilly CEO David Ricks
Eli Lilly picks up gene therapy player Prevail in deal worth $1B+, making good on bolt-on pledge from earlier this year
Back in January, Indiana’s Eli Lilly touted its plan to tack on a suite of mostly early-stage assets in targeted therapeutic areas a la its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
